Wednesday Afternoon’s Analyst Upgrades and Downgrades: Lennar, StoneCo, Vertex Energy and More

Wednesday afternoon's analyst upgrades and downgrades included American Water Works, Corvus Pharmaceuticals, ImmunoGen, Lennar, StoneCo and Vertex Energy.

Published December 1, 2021, 12:05pm ET · 2 min read

A dynamic, dark blue-toned image showing an overlay of financial candlestick and line charts over a blurred one-hundred dollar bill featuring Benjamin Franklin. In the background, out-of-focus city lights create a bokeh effect, suggesting a bustling urban financial environment.
An overlay of financial charts on a hundred-dollar bill, set against a blurred city lights background, illustrates the dynamic growth in the optics stock market. © honglouwawa / Getty Images

Tuesday saw a big drop across the broad markets, but on Wednesday things bounced back. This is not to say investors have lost focus on Omicron or Federal Reserve concerns, but when stocks slid significantly on last Friday and then again on Tuesday, it did provide a good buying opportunity. At the same time, economists are looking forward to Friday to see November’s unemployment report.

24/7 Wall St. is reviewing some big analyst calls seen on Wednesday. We have included the latest call on each stock, as well as a recent trading history and the consensus targets among analysts. Note that analyst calls seen earlier in the day were on Beyond Meat, Capital One, DoorDash, Foot Locker, Krispy Kreme and more.

American Water Works Co. Inc. (NYSE: AWK | AWK Price Prediction): Wells Fargo downgraded the stock to an Underweight rating from Equal Weight and lowered the price target to $170 from $171. Shares were trading around $170 on Wednesday, and the 52-week range is $131.01 to $189.35.

Corvus Pharmaceuticals Inc. (NASDAQ: CRVS): Jefferies resumed coverage with a Buy rating and an $8 price target. Shares were last seen near $3.50 on Wednesday, and they have a 52-week range of $1.86 to $9.54.

[nativounit]

ImmunoGen Inc. (NASDAQ: IMGN): The Jefferies upgrade to Buy from Hold included a price target hike to $12 from $7. Shares were trading around $7 on Wednesday, and the consensus target price is $10.50.

Lennar Corp. (NYSE: LEN): Goldman Sachs raised its Neutral rating to Buy and changed the $108 price target to $140. The consensus price target is $120.36, and shares were trading near $110 apiece.

StoneCo Ltd. (NASDAQ: STNE): Scotiabank started coverage with a Sector Perform rating. The 52-week trading range is $15.00 to $95.12, and shares were last seen near $16.

Supernus Pharmaceuticals Inc. (NASDAQ: SUPN): Jefferies resumed coverage with a Buy rating and raised the $40 price target to $44. The 52-week trading range is $20.81 to $34.50, and the share price was near $32.

Vertex Energy Inc. (NASDAQ: VTNR): Credit Suisse started coverage with an Outperform rating and a $13 price target. Shares were trading near $6 on Wednesday, and the consensus price target is $19.00.
[recirclink id=1002349]
Now is the time to reduce risk and more to safer ideas. Top-quality health care stocks may be the way to go for the rest of 2021 and in 2022, and these five Dividend Aristocrats make good sense now for worried investors.
[wallst_email_signup]

Contact [email protected] for any questions or corrections.

Chris Lange

Chris Lange is a financial and geopolitical writer with more than a decade of experience covering a myriad of topics. He has published thousands of articles for 24/7 Wall St., with past coverage focused heavily on stocks, IPOs, healthcare, defense, global affairs, and technology.

His work has been quoted, or referenced by a number of outlets including Business Insider, USA Today, Yahoo Finance, MSN, The Motley Fool, and many other publications. A graduate of Southwestern University, he studied business with a focus on investments and has previous experience in banking and startups.

When not reading or writing the news, he is following his passion for Lacrosse, playing chess, or building solar projects with his dad.

All articles →